Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 14 of the 32 sources its claims cite were checked for support.
Abstract
BACKGROUND: In a phase 1-2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma. Daratumumab, a monoclonal antibody targeting CD38 protein, has shown survival benefit in patients with multiple myeloma. METHODS: In this phase 3 trial, we randomly assigned patients with one to three previous lines of therapy to receive combination therapy with teclistamab-daratumumab or daratumumab combined with dexamethasone plus the investigator's choice of pomalidomide (DPd) or bortezomib (DVd) - the DPd or DVd group. The primary end point was progression-free survival, as assessed by an independent review committee. RESULTS: ; 58.4% vs. 17.1%) (P<0.001 for all comparisons). Serious adverse events occurred in 70.7% of the patients in the teclistamab-daratumumab group and in 62.4% of those in the DPd or DVd group; death from adverse events occurred in 7.1% and 5.9%, respectively. CONCLUSIONS: In patients with multiple myeloma who had received one to three previous lines of therapy, those in the teclistamab-daratumumab group had significantly longer progression-free survival than those in the DPd or DVd group. (Funded by Johnson & Johnson; ClinicalTrials.gov number, NCT05083169.).
Overview
CoChat Summary
## TL;DR
MajesTEC-3 is a phase 3 randomized trial in relapsed/refractory multiple myeloma showing that teclistamab plus daratumumab (Tec-Dara) improved progression-free survival and overall survival versus standard daratumumab-based care. The combination also increased response depth and MRD negativity, but it came with frequent adverse events, including infections and treatment-emergent fatal events.
## Key findings
- 587 patients were randomized (Tec-Dara, n=291; DPd/DVd, n=296); median follow-up was 34.5 months.
- Estimated 36-month progression-free survival was 83.4% with Tec-Dara versus 29.7% with DPd/DVd; HR 0.17 (95% CI, 0.12–0.23; P<0.0001).
- Complete response or better occurred in 81.8% vs. 32.1%, overall response in 89.0% vs. 75.3%, and MRD negativity at 10^-5 in 58.4% vs. 17.1% with Tec-Dara vs. DPd/DVd, all significantly favored Tec-Dara.
- Estimated 36-month overall survival was 83.3% with Tec-Dara and 65.0% with DPd/DVd (P<0.0001); time to worsening of symptoms also favored Tec-Dara (36-month event-free rate 75.6% vs. 63.3%; HR 0.50).
- Safety was substantial in both groups: grade 3/4 adverse events occurred in 95.1% vs. 96.6%, deaths due to treatment-emergent adverse events in 7.1% vs. 5.9%, and grade 3/4 infections in 54.1% vs. 43.4% with Tec-Dara vs. DPd/DVd.
## Methods
- Multicenter, open-label, phase 3 randomized study across 150 sites in 20 countries; patients were randomized 1:1 to Tec-Dara or investigator’s choice of DPd/DVd.
- Eligible patients had 1–3 prior lines of antimyeloma therapy, including a proteasome inhibitor and lenalidomide, with progression on or after the last regimen; key exclusions included prior BCMA-directed therapy and anti-CD38 refractoriness.
- Primary endpoint was progression-free survival by blinded independent review committee; key secondary endpoints included ≥CR, overall response, MRD negativity, overall survival, and symptom worsening; analyses used stratified log-rank tests, Cox models, and hierarchical testing.
## Limitations
- The paper states that the width of confidence intervals was not adjusted for multiplicity and “may not be used in place of hypothesis testing.”
- The paper notes that subgroup findings for prior anti-CD38 exposure, age >75 years, and ECOG performance status 2 were based on “a few patients” or “small” subgroups; this limits certainty in those strata.
- Evident from the text: the study was open-label, which can introduce bias in subjective outcomes such as symptom reporting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
9 Valid · 3 Not valid · 4 Not checked · 51 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Results further emphasize the importance of early infection prevention in patients receiving bispecific antibodies, including use of immunoglobulin replacement per IMWG guidelines to reduce high-grade infections.36–40”
§ Teclistamab plus Daratumumab in Relapsed Refractory Multiple Myeloma > Discussion After almost 3 years of median follow-up, Tec-Dara significantly improved progression-free survival in patients with RRMM exposed to 1–3 prior lines, with an 83% reduction in the hazard of disease progression or death versus standard-of-care DPd/DVd. Progression-free survival benefits favored Tec-Dara across all prespecified subgroups. Furthermore, Tec-Dara significantly improved ≥CR and overall response rates (including response durability), MRD-negativity rate (10−5), overall survival, and time to worsening of symptoms, versus DPd/DVd. Treating RRMM is increasingly challenging, with progressive immune dysfunction, multiple relapses, and often poor survival outcomes.24 Emerging treatment options in this setting include novel BCMA-targeting therapies, which have reshaped the therapeutic landscape. Ciltacabtagene autoleucel, a BCMA autologous CAR-T therapy, has significantly improved progression-free and overall survival versus DPd/PVd, with an improving adverse event profile from late to earlier lines of treatment.5,25 Belantamab mafodotin, a BCMA-directed antibody-drug conjugate, has also demonstrated improved progression-free and overall survival in early-line RRMM.26,27 Although grade ≥3 infections have been reported in up to half of patients receiving belantamab mafodotin, along with high incidences of ocular toxicity, regular ophthalmic monitoring, dose modifications, and supportive care can inform management decisions.26,28 Other bispecific antibodies with activity in advanced myeloma and targeting BCMA, elranatamab29 and linvoseltamab,30 as well as GPRC5D, talquetamab,31 are being evaluated in earlier line RRMM. Tec-Dara is a synergistic immunotherapy combination that utilizes subcutaneous administration, step-up dosing, and the well-established daratumumab dosing schedule. With the significant progression-free and overall survival benefit, and low rates of grade 2 cytokine release syndrome, Tec-Dara may address the need for a highly effective regimen and community accessibility. Guidelines on prophylactic tocilizumab and well-established infection protocols will further inform community adoption; however, treatment choice will be guided by individual risk–benefit considerations, access, and patient choice. With ciltacabtagene autoleucel and Tec-Dara offering immunotherapy–based options with plateauing survival curves, we may be entering a new era of resetting survival expectations in a malignancy historically described as incurable. As shown, Tec-Dara conferred a significant progression-free survival benefit versus DPd/DVd.5,13,26,28,32 Progression-free survival benefit with Tec-Dara was observed despite DPd/DVd (median progression-free survival 18.1 months) outperforming expectations per APOLLO (DPd, 12.4 months), CASTOR (DVd, 16.7 months), and CARTITUDE-4 (DPd/PVd, 11.8 months) studies.5,12,33 Although only a few patients on MajesTEC-3 had received prior anti-CD38 therapy, progression-free survival benefit appeared to be obtained with Tec-Dara in this subgroup. The proportion of patients over age 75 years or with an Eastern Cooperative Oncology Group performance status score of 2 were also small but consistent with results reported in studies of similar populations;5,26,28,33 a progression-free survival benefit was still observed with Tec-Dara in these subgroups. Ongoing studies and real-world evidence will build on the body of evidence in these groups. Finally, in the Tec-Dara group, more than 90% of patients alive at 6 months remained alive at 30 months, suggesting a plateau in the survival curve. The Tec-Dara safety profile was well characterized. No new adverse events were noted compared to the safety profile of each individual agent. Cytokine release syndrome incidence was lower than that observed with teclistamab monotherapy in MajesTEC-1 (60.1% vs. 72.1%, respectively),8 with most events being grade 1 and occurring during the step-up dosing schedule. Of note, prophylactic tocilizumab, not permitted in this study, is now recommended in guidelines and reduces the incidence and severity of cytokine release syndrome.34,35 Nearly all patients experienced a grade 3 or higher adverse event (7.1% deaths due to treatment-emergent adverse events), most of which were cytopenias and infections. These events can be controlled with established immunoglobulin replacement and infection prevention and treatment protocols. MajesTEC-3 enrollment began during the COVID-19 pandemic, before the establishment of optimal infection prevention strategies for patients receiving BCMA-directed therapy. Following reinforced immunoglobulin recommendations and adherence to infection management recommendations, 1 fatal infection was noted with Tec-Dara and new-onset grade ≥3 infections decreased from 6 months onward, coinciding with monthly dosing. Results further emphasize the importance of early infection prevention in patients receiving bispecific antibodies, including use of immunoglobulin replacement per IMWG guidelines to reduce high-grade infections.36–40 Notably, Tec-Dara was administered per approved daratumumab dosing schedule, with monthly teclistamab dosing from cycle 7 onwards, potentially easing treatment burden and providing a regimen familiar to healthcare providers. Results support the potential administration of this off-the-shelf combination in a community-based setting, as demonstrated in the real-world with teclistamab monotherapy.41 In conclusion, MajesTEC-3 demonstrates a statistically significant benefit of Tec-Dara on progression-free survival and overall survival. It is associated with a risk of adverse events; however, the risks can be ameliorated with the use of established protocols. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
What the sources say
- Partly supportedcites [36] sourceExperimental — accuracy not yet measured
The Consensus recommendations (Risk factors for infection; page not provided) recommend monthly IVIG for patients with immunoparesis receiving bispecific antibodies, and discuss immunoglobulin replacement for patients at particular infection risk. The passages do not identify these as IMWG guidelines or report that early replacement reduces high-grade infections; the claim states that outcome more firmly than this source supports. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [37] source
- Partly supportedcites [38] sourceExperimental — accuracy not yet measured
Our copy supports the core of the claim: in the self-controlled case series of 37 anti-BCMA bispecific antibody patients, the grade 3-5 infection rate was 90% lower on IVIg (IRR 0.10; 95% CI 0.01-0.80; P=0.0307; Introduction and Discussion), and the authors argue for early/primary prophylaxis rather than the traditional reactive strategy, listing IVIg q4 weeks among their prevention recommendations (Table 3, Discussion). Two attributed elements are not supported: (1) the 'per IMWG guidelines' provenance — IMWG criteria are used in our copy only for disease-response assessment (Definitions, ref 40), while the traditional immunoglobulin-replacement recommendations are credited to other guidelines (refs 24-26: Anderson 2007 IVIG-for-hematologic-conditions guidelines, Terpos 2015 European Myeloma Network, Girmenia 2019 expert panel); (2) the claim states reduction as established fact, whereas the paper hedges it as a retrospective, nonrandomly administered association 'suggesting a role for IVIg as primary prophylaxis' pending randomized confirmation. (LLM, conf=0.78)
- Not matchedcites [39]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [40] source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Cytokine release syndrome incidence was lower than that observed with teclistamab monotherapy in MajesTEC-1 (60.1% vs. 72.1%, respectively),8 with most events being grade 1 and occurring during the step-up dosing schedule.”
§ Teclistamab plus Daratumumab in Relapsed Refractory Multiple Myeloma > Discussion After almost 3 years of median follow-up, Tec-Dara significantly improved progression-free survival in patients with RRMM exposed to 1–3 prior lines, with an 83% reduction in the hazard of disease progression or death versus standard-of-care DPd/DVd. Progression-free survival benefits favored Tec-Dara across all prespecified subgroups. Furthermore, Tec-Dara significantly improved ≥CR and overall response rates (including response durability), MRD-negativity rate (10−5), overall survival, and time to worsening of symptoms, versus DPd/DVd. Treating RRMM is increasingly challenging, with progressive immune dysfunction, multiple relapses, and often poor survival outcomes.24 Emerging treatment options in this setting include novel BCMA-targeting therapies, which have reshaped the therapeutic landscape. Ciltacabtagene autoleucel, a BCMA autologous CAR-T therapy, has significantly improved progression-free and overall survival versus DPd/PVd, with an improving adverse event profile from late to earlier lines of treatment.5,25 Belantamab mafodotin, a BCMA-directed antibody-drug conjugate, has also demonstrated improved progression-free and overall survival in early-line RRMM.26,27 Although grade ≥3 infections have been reported in up to half of patients receiving belantamab mafodotin, along with high incidences of ocular toxicity, regular ophthalmic monitoring, dose modifications, and supportive care can inform management decisions.26,28 Other bispecific antibodies with activity in advanced myeloma and targeting BCMA, elranatamab29 and linvoseltamab,30 as well as GPRC5D, talquetamab,31 are being evaluated in earlier line RRMM. Tec-Dara is a synergistic immunotherapy combination that utilizes subcutaneous administration, step-up dosing, and the well-established daratumumab dosing schedule. With the significant progression-free and overall survival benefit, and low rates of grade 2 cytokine release syndrome, Tec-Dara may address the need for a highly effective regimen and community accessibility. Guidelines on prophylactic tocilizumab and well-established infection protocols will further inform community adoption; however, treatment choice will be guided by individual risk–benefit considerations, access, and patient choice. With ciltacabtagene autoleucel and Tec-Dara offering immunotherapy–based options with plateauing survival curves, we may be entering a new era of resetting survival expectations in a malignancy historically described as incurable. As shown, Tec-Dara conferred a significant progression-free survival benefit versus DPd/DVd.5,13,26,28,32 Progression-free survival benefit with Tec-Dara was observed despite DPd/DVd (median progression-free survival 18.1 months) outperforming expectations per APOLLO (DPd, 12.4 months), CASTOR (DVd, 16.7 months), and CARTITUDE-4 (DPd/PVd, 11.8 months) studies.5,12,33 Although only a few patients on MajesTEC-3 had received prior anti-CD38 therapy, progression-free survival benefit appeared to be obtained with Tec-Dara in this subgroup. The proportion of patients over age 75 years or with an Eastern Cooperative Oncology Group performance status score of 2 were also small but consistent with results reported in studies of similar populations;5,26,28,33 a progression-free survival benefit was still observed with Tec-Dara in these subgroups. Ongoing studies and real-world evidence will build on the body of evidence in these groups. Finally, in the Tec-Dara group, more than 90% of patients alive at 6 months remained alive at 30 months, suggesting a plateau in the survival curve. The Tec-Dara safety profile was well characterized. No new adverse events were noted compared to the safety profile of each individual agent. Cytokine release syndrome incidence was lower than that observed with teclistamab monotherapy in MajesTEC-1 (60.1% vs. 72.1%, respectively),8 with most events being grade 1 and occurring during the step-up dosing schedule. Of note, prophylactic tocilizumab, not permitted in this study, is now recommended in guidelines and reduces the incidence and severity of cytokine release syndrome.34,35 Nearly all patients experienced a grade 3 or higher adverse event (7.1% deaths due to treatment-emergent adverse events), most of which were cytopenias and infections. These events can be controlled with established immunoglobulin replacement and infection prevention and treatment protocols. MajesTEC-3 enrollment began during the COVID-19 pandemic, before the establishment of optimal infection prevention strategies for patients receiving BCMA-directed therapy. Following reinforced immunoglobulin recommendations and adherence to infection management recommendations, 1 fatal infection was noted with Tec-Dara and new-onset grade ≥3 infections decreased from 6 months onward, coinciding with monthly dosing. Results further emphasize the importance of early infection prevention in patients receiving bispecific antibodies, including use of immunoglobulin replacement per IMWG guidelines to reduce high-grade infections.36–40 Notably, Tec-Dara was administered per approved daratumumab dosing schedule, with monthly teclistamab dosing from cycle 7 onwards, potentially easing treatment burden and providing a regimen familiar to healthcare providers. Results support the potential administration of this off-the-shelf combination in a community-based setting, as demonstrated in the real-world with teclistamab monotherapy.41 In conclusion, MajesTEC-3 demonstrates a statistically significant benefit of Tec-Dara on progression-free survival and overall survival. It is associated with a risk of adverse events; however, the risks can be ameliorated with the use of established protocols. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
What the sources say
- Supportedcites [8] source
The Results > Safety passage reports cytokine release syndrome in 119 of 165 MajesTEC-1 patients receiving teclistamab (72.1%). The cited paper supplies the monotherapy comparator; the 60.1% Tec-Dara figure is the citing study’s own result, not a result attributed to this source. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Teclistamab, a bispecific antibody targeting CD3×BCMA,6 demonstrated deep and durable responses in heavily pretreated RRMM in the phase 1/2 MajesTEC-1 study.7,8”
§ Teclistamab plus Daratumumab in Relapsed Refractory Multiple Myeloma > Introduction
What the sources say
- Not matchedcites [7]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Supportedcites [8] source
The Discussion states that the phase 1–2 study found deep and durable responses to teclistamab in patients with triple-class–exposed relapsed or refractory multiple myeloma. The Methods identify the study as MajesTEC-1, and the Results report a median of five previous therapy lines and a median response duration of 18.4 months. (LLM, conf=0.95)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Tec-Dara resulted in a significantly lower risk of disease progression or death than DPd/DVd (P<0.0001); the P value crossed the prespecified stopping boundary for superiority for the first interim analysis (P=0.0139).”
- Also stated in: § Discussion After almost 3 years of median follow-up, Tec-Dara significantly improved progression-free survival in patients with RRMM exposed to 1–3 prior lines, with an 83% reduction in the hazard of disease progression or death versus standard-of-care DPd/DVd. Progression-free survival benefits favored Tec-Dara across all prespecified subgroups. Furthermore, Tec-Dara significantly improved ≥CR and overall response rates (including response durability), MRD-negativity rate (10−5), overall survival, and time to worsening of symptoms, versus DPd/DVd. Treating RRMM is increasingly challenging, with progressive immune dysfunction, multiple relapses, and often poor survival outcomes.24 Emerging treatment options in this setting include novel BCMA-targeting therapies, which have reshaped the therapeutic landscape. Ciltacabtagene autoleucel, a BCMA autologous CAR-T therapy, has significantly improved progression-free and overall survival versus DPd/PVd, with an improving adverse event profile from late to earlier lines of treatment.5,25 Belantamab mafodotin, a BCMA-directed antibody-drug conjugate, has also demonstrated improved progression-free and overall survival in early-line RRMM.26,27 Although grade ≥3 infections have been reported in up to half of patients receiving belantamab mafodotin, along with high incidences of ocular toxicity, regular ophthalmic monitoring, dose modifications, and supportive care can inform management decisions.26,28 Other bispecific antibodies with activity in advanced myeloma and targeting BCMA, elranatamab29 and linvoseltamab,30 as well as GPRC5D, talquetamab,31 are being evaluated in earlier line RRMM. Tec-Dara is a synergistic immunotherapy combination that utilizes subcutaneous administration, step-up dosing, and the well-established daratumumab dosing schedule. With the significant progression-free and overall survival benefit, and low rates of grade 2 cytokine release syndrome, Tec-Dara may address the need for a highly effective regimen and community accessibility. Guidelines on prophylactic tocilizumab and well-established infection protocols will further inform community adoption; however, treatment choice will be guided by individual risk–benefit considerations, access, and patient choice. With ciltacabtagene autoleucel and Tec-Dara offering immunotherapy–based options with plateauing survival curves, we may be entering a new era of resetting survival expectations in a malignancy historically described as incurable. As shown, Tec-Dara conferred a significant progression-free survival benefit versus DPd/DVd.5,13,26,28,32 Progression-free survival benefit with Tec-Dara was observed despite DPd/DVd (median progression-free survival 18.1 months) outperforming expectations per APOLLO (DPd, 12.4 months), CASTOR (DVd, 16.7 months), and CARTITUDE-4 (DPd/PVd, 11.8 months) studies.5,12,33 Although only a few patients on MajesTEC-3 had received prior anti-CD38 therapy, progression-free survival benefit appeared to be obtained with Tec-Dara in this subgroup. The proportion of patients over age 75 years or with an Eastern Cooperative Oncology Group performance status score of 2 were also small but consistent with results reported in studies of similar populations;5,26,28,33 a progression-free survival benefit was still observed with Tec-Dara in these subgroups. Ongoing studies and real-world evidence will build on the body of evidence in these groups. Finally, in the Tec-Dara group, more than 90% of patients alive at 6 months remained alive at 30 months, suggesting a plateau in the survival curve. The Tec-Dara safety profile was well characterized. No new adverse events were noted compared to the safety profile of each individual agent. Cytokine release syndrome incidence was lower than that observed with teclistamab monotherapy in MajesTEC-1 (60.1% vs. 72.1%, respectively),8 with most events being grade 1 and occurring during the step-up dosing schedule. Of note, prophylactic tocilizumab, not permitted in this study, is now recommended in guidelines and reduces the incidence and severity of cytokine release syndrome.34,35 Nearly all patients experienced a grade 3 or higher adverse event (7.1% deaths due to treatment-emergent adverse events), most of which were cytopenias and infections. These events can be controlled with established immunoglobulin replacement and infection prevention and treatment protocols. MajesTEC-3 enrollment began during the COVID-19 pandemic, before the establishment of optimal infection prevention strategies for patients receiving BCMA-directed therapy. Following reinforced immunoglobulin recommendations and adherence to infection management recommendations, 1 fatal infection was noted with Tec-Dara and new-onset grade ≥3 infections decreased from 6 months onward, coinciding with monthly dosing. Results further emphasize the importance of early infection prevention in patients receiving bispecific antibodies, including use of immunoglobulin replacement per IMWG guidelines to reduce high-grade infections.36–40 Notably, Tec-Dara was administered per approved daratumumab dosing schedule, with monthly teclistamab dosing from cycle 7 onwards, potentially easing treatment burden and providing a regimen familiar to healthcare providers. Results support the potential administration of this off-the-shelf combination in a community-based setting, as demonstrated in the real-world with teclistamab monotherapy.41 In conclusion, MajesTEC-3 demonstrates a statistically significant benefit of Tec-Dara on progression-free survival and overall survival. It is associated with a risk of adverse events; however, the risks can be ameliorated with the use of established protocols. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. · boosted
“After almost 3 years of median follow-up, Tec-Dara significantly improved progression-free survival in patients with RRMM exposed to 1–3 prior lines, with an 83% reduction in the hazard of disease progression or death versus standard-of-care DPd/DVd.”
§ Teclistamab plus Daratumumab in Relapsed Refractory Multiple Myeloma > Results > Efficacy
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion After almost 3 years of median follow-up, Tec-Dara significantly improved progression-free survival in patients with RRMM exposed to 1–3 prior lines, with an 83% reduction in the hazard of disease progression or death versus standard-of-care DPd/DVd. Progression-free survival benefits favored Tec-Dara across all prespecified subgroups. Furthermore, Tec-Dara significantly improved ≥CR and overall response rates (including response durability), MRD-negativity rate (10−5), overall survival, and time to worsening of symptoms, versus DPd/DVd. Treating RRMM is increasingly challenging, with progressive immune dysfunction, multiple relapses, and often poor survival outcomes.24 Emerging treatment options in this setting include novel BCMA-targeting therapies, which have reshaped the therapeutic landscape. Ciltacabtagene autoleucel, a BCMA autologous CAR-T therapy, has significantly improved progression-free and overall survival versus DPd/PVd, with an improving adverse event profile from late to earlier lines of treatment.5,25 Belantamab mafodotin, a BCMA-directed antibody-drug conjugate, has also demonstrated improved progression-free and overall survival in early-line RRMM.26,27 Although grade ≥3 infections have been reported in up to half of patients receiving belantamab mafodotin, along with high incidences of ocular toxicity, regular ophthalmic monitoring, dose modifications, and supportive care can inform management decisions.26,28 Other bispecific antibodies with activity in advanced myeloma and targeting BCMA, elranatamab29 and linvoseltamab,30 as well as GPRC5D, talquetamab,31 are being evaluated in earlier line RRMM. Tec-Dara is a synergistic immunotherapy combination that utilizes subcutaneous administration, step-up dosing, and the well-established daratumumab dosing schedule. With the significant progression-free and overall survival benefit, and low rates of grade 2 cytokine release syndrome, Tec-Dara may address the need for a highly effective regimen and community accessibility. Guidelines on prophylactic tocilizumab and well-established infection protocols will further inform community adoption; however, treatment choice will be guided by individual risk–benefit considerations, access, and patient choice. With ciltacabtagene autoleucel and Tec-Dara offering immunotherapy–based options with plateauing survival curves, we may be entering a new era of resetting survival expectations in a malignancy historically described as incurable. As shown, Tec-Dara conferred a significant progression-free survival benefit versus DPd/DVd.5,13,26,28,32 Progression-free survival benefit with Tec-Dara was observed despite DPd/DVd (median progression-free survival 18.1 months) outperforming expectations per APOLLO (DPd, 12.4 months), CASTOR (DVd, 16.7 months), and CARTITUDE-4 (DPd/PVd, 11.8 months) studies.5,12,33 Although only a few patients on MajesTEC-3 had received prior anti-CD38 therapy, progression-free survival benefit appeared to be obtained with Tec-Dara in this subgroup. The proportion of patients over age 75 years or with an Eastern Cooperative Oncology Group performance status score of 2 were also small but consistent with results reported in studies of similar populations;5,26,28,33 a progression-free survival benefit was still observed with Tec-Dara in these subgroups. Ongoing studies and real-world evidence will build on the body of evidence in these groups. Finally, in the Tec-Dara group, more than 90% of patients alive at 6 months remained alive at 30 months, suggesting a plateau in the survival curve. The Tec-Dara safety profile was well characterized. No new adverse events were noted compared to the safety profile of each individual agent. Cytokine release syndrome incidence was lower than that observed with teclistamab monotherapy in MajesTEC-1 (60.1% vs. 72.1%, respectively),8 with most events being grade 1 and occurring during the step-up dosing schedule. Of note, prophylactic tocilizumab, not permitted in this study, is now recommended in guidelines and reduces the incidence and severity of cytokine release syndrome.34,35 Nearly all patients experienced a grade 3 or higher adverse event (7.1% deaths due to treatment-emergent adverse events), most of which were cytopenias and infections. These events can be controlled with established immunoglobulin replacement and infection prevention and treatment protocols. MajesTEC-3 enrollment began during the COVID-19 pandemic, before the establishment of optimal infection prevention strategies for patients receiving BCMA-directed therapy. Following reinforced immunoglobulin recommendations and adherence to infection management recommendations, 1 fatal infection was noted with Tec-Dara and new-onset grade ≥3 infections decreased from 6 months onward, coinciding with monthly dosing. Results further emphasize the importance of early infection prevention in patients receiving bispecific antibodies, including use of immunoglobulin replacement per IMWG guidelines to reduce high-grade infections.36–40 Notably, Tec-Dara was administered per approved daratumumab dosing schedule, with monthly teclistamab dosing from cycle 7 onwards, potentially easing treatment burden and providing a regimen familiar to healthcare providers. Results support the potential administration of this off-the-shelf combination in a community-based setting, as demonstrated in the real-world with teclistamab monotherapy.41 In conclusion, MajesTEC-3 demonstrates a statistically significant benefit of Tec-Dara on progression-free survival and overall survival. It is associated with a risk of adverse events; however, the risks can be ameliorated with the use of established protocols. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. · boosted
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The proportion of patients achieving ≥CR was significantly higher with Tec-Dara versus DPd/DVd (81.8% vs. 32.1%), with a risk ratio (post-hoc) of 2.55 (95% CI, 2.14–3.03; Table 2).”
§ Teclistamab plus Daratumumab in Relapsed Refractory Multiple Myeloma > Results > Efficacy
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
23 more claims
Create a free account to see all 67 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 26
- Borderline: one of the tests for a substantial claim is unclear. 1
Citations
Cites
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675 · cited 1×
“23”
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061 · cited 1×
“18 MRD was assessed in patients with suspected ≥CR, and at 6, 12, 18, and 24 months post-cycle 1 day 1 (±1 month) for patients with confirmed ≥CR. Serum was collected to assess teclistamab and daratumumab pharmacokinetics and immunogenicity.”
Self-citationDaratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Self-citationTeclistamab in Relapsed or Refractory Multiple Myeloma
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269 · cited 1×
“Cytokine release syndrome incidence was lower than that observed with teclistamab monotherapy in MajesTEC-1 (60.1% vs. 72.1%, respectively), 8 with most events being grade 1 and occurring during the step-up dosing schedule.”
InfluentialSelf-citationDaratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817249 · Cited by 1,045
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036 · cited 1×
“16– 18 Disease evaluations were performed centrally; imaging and bone marrow analysis for response were performed locally.”
Self-citationCilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303379 · Cited by 827 · cited 5×
“As shown, Tec-Dara conferred a significant progression-free survival benefit versus DPd/ DVd. 5,13,26,28,32 Progression-free survival benefit with Tec-Dara was observed despite DPd/DVd (median progression-free survival 18.1 months) outperforming expectations per APOLLO (DPd, 12.4 months), CASTOR…”
InfluentialSelf-citationDaratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312054 · Cited by 599
Self-citationDimopoulos, M. A., Terpos, E., Boccadoro, M., Delimpasi, S., Beksac, M., Katodritou, E., Moreau, P., Baldini, L., Symeonidis, A., Bila, J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00128-5 · Cited by 344 · cited 2×
“18 MRD was assessed in patients with suspected ≥CR, and at 6, 12, 18, and 24 months post-cycle 1 day 1 (±1 month) for patients with confirmed ≥CR. Serum was collected to assess teclistamab and daratumumab pharmacokinetics and immunogenicity.”
Self-citationRaje, N. S., Anaissie, E., Kumar, S. K., Lonial, S., Martin, T., Gertz, M. A., Krishnan, A., Hari, P., Ludwig, H., O'Donnell, E., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00283-0 · Cited by 212
Raje, N., Anderson, K., Einsele, H., Efebera, Y., Gay, F., Hammond, S. P., Lesokhin, A. M., Lonial, S., Ludwig, H., Moreau, P., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00879-7 · Cited by 209 · cited 1×
“36– 40 Notably, Tec-Dara was administered per approved daratumumab dosing schedule, with monthly teclistamab dosing from cycle 7 onwards, potentially easing treatment burden and providing a regimen familiar to healthcare providers.”
Self-citationBelantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
Hungria, V., Robak, P., Hus, M., Zherebtsova, V., Ward, C., Ho, P. J., Ribas de Almeida, A. C., Hajek, R., Kim, K., Grosicki, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2405090 · Cited by 199 · cited 2×
“…of patients over age 75 years or with an Eastern Cooperative Oncology Group performance status score of 2 were also small but consistent with results reported in studies of similar populations; 5,26,28,33 a progression-free survival benefit was still observed with Tec-Dara in these subgroups.”
InfluentialSelf-citationBelantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
Dimopoulos, M. A., Beksac, M., Pour, L., Delimpasi, S., Vorobyev, V., Quach, H., Spicka, I., Radocha, J., Robak, P., Kim, K., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403407 · Cited by 189 · cited 7×
“…mafodotin, a BCMA-directed antibody-drug conjugate, has also demonstrated improved progression-free and overall survival in early-line RRMM. 26,27 Although grade ≥3 infections have been reported in up to half of patients receiving belantamab mafodotin, along with high incidences of ocular…”
InfluentialSelf-citationJagannath, S., Martin, T. G., Lin, Y., Cohen, A. D., Raje, N. S., Htut, M., Deol, A., Agha, M., Berdeja, J. G., Lesokhin, A. M., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00760 · Cited by 183
Mateos, M.-V., Sonneveld, P., Hungria, V., Nooka, A. K., Estell, J. A., Barreto, W., Corradini, P., Min, C.-K., Medvedova, E., Weisel, K., et al. (2020) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2019.09.623 · Cited by 160 · cited 2×
“…of patients over age 75 years or with an Eastern Cooperative Oncology Group performance status score of 2 were also small but consistent with results reported in studies of similar populations; 5,26,28,33 a progression-free survival benefit was still observed with Tec-Dara in these subgroups.”
Self-citationLancman, G., Parsa, K., Kotlarz, K., Avery, L., Lurie, A., Lieberman-Cribbin, A., Cho, H. J., Parekh, S. S., Richard, S., Richter, J., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0049 · Cited by 140
Fonseca, R., Usmani, S. Z., Mehra, M., Slavcev, M., He, J., Cote, S., Lam, A., Ukropec, J., Maiese, E. M., Nair, S., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07503-y · Cited by 127
Usmani, S. Z., Quach, H., Mateos, M., Landgren, O., Leleu, X. P., Siegel, D. S. D., Weisel, K. C., Shu, X., Li, C., & Dimopoulos, M. A. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010026 · Cited by 115 · cited 1×
“As shown, Tec-Dara conferred a significant progression-free survival benefit versus DPd/ DVd. 5,13,26,28,32 Progression-free survival benefit with Tec-Dara was observed despite DPd/DVd (median progression-free survival 18.1 months) outperforming expectations per APOLLO (DPd, 12.4 months), CASTOR…”
InfluentialSelf-citationMartin, T., Dimopoulos, M.-A., Mikhael, J., Yong, K., Capra, M., Facon, T., Hajek, R., Špička, I., Baker, R., Kim, K., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00797-8 · Cited by 101 · cited 1×
“As shown, Tec-Dara conferred a significant progression-free survival benefit versus DPd/ DVd. 5,13,26,28,32 Progression-free survival benefit with Tec-Dara was observed despite DPd/DVd (median progression-free survival 18.1 months) outperforming expectations per APOLLO (DPd, 12.4 months), CASTOR…”
InfluentialSelf-citationFrerichs, K. A., Broekmans, M. E. C., Marin Soto, J. A., van Kessel, B., Heymans, M. W., Holthof, L. C., Verkleij, C. P. M., Boominathan, R., Vaidya, B., Sendecki, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2299 · Cited by 94
Scott, S. A., Marin, E. M., Maples, K. T., Joseph, N. S., Hofmeister, C. C., Gupta, V. A., Dhodapkar, M. V., Kaufman, J. L., Lonial, S., & Nooka, A. K. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00963-y · Cited by 63 · cited 1×
“34,35 Nearly all patients experienced a grade 3 or higher adverse event (7.1% deaths due to treatment-emergent adverse events), most of which were cytopenias and infections.”
InfluentialSelf-citationKumar, S., Baizer, L., Callander, N. S., Giralt, S. A., Hillengass, J., Freidlin, B., Hoering, A., Richardson, P. G., Schwartz, E. I., Reiman, A., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00695-5 · Cited by 62
Mateos, M., Weisel, K. C., Stefano, V. D., Goldschmidt, H., Delforge, M., Mohty, M., Dytfeld, D., Angelucci, E., Vincent, L., Perrot, A., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02404-6 · Cited by 51
Self-citationClarification of the definition of complete response in multiple myeloma
Durie, B. G. M., Miguel, J. F. S., Blade, J., Rajkumar, S. V., & on behalf of the International Myeloma Working Group (2015) · Leukemia · doi:10.1038/leu.2015.290 · Cited by 42
Chari, A., Kaufman, J. L., Laubach, J. P., Sborov, D. W., Reeves, B., Rodriguez, C., Silbermann, R. W., Costa, L. J., Anderson, L. D., Nathwani, N., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01088-6 · Cited by 40
Self-citationWang, P. F., Yee, C. W., Gorsh, B., Zichlin, M. L., Paka, P., Bhak, R. H., Boytsov, N., Khanal, A., Noman, A., DerSarkissian, M., et al. (2023) · Leukemia & Lymphoma · doi:10.1080/10428194.2022.2140284 · Cited by 35
Hungria, V., Robak, P., Hus, M., Zherebtsova, V., Ward, C., Ho, P. J., Hájek, R., Kim, K., Grosicki, S., Sia, H., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00330-4 · Cited by 35 · cited 1×
“…mafodotin, a BCMA-directed antibody-drug conjugate, has also demonstrated improved progression-free and overall survival in early-line RRMM. 26,27 Although grade ≥3 infections have been reported in up to half of patients receiving belantamab mafodotin, along with high incidences of ocular…”
Self-citationCohen, Y. C., Moreau, P., Tolbert, J. A., Qin, X., Ma, X., Vieyra, D. S., Langlois, A., Courtoux, C., Terry, W., Pei, L., et al. (2022) · Blood · doi:10.1182/blood-2022-162733 · Cited by 26
Self-citationGrosicki, S., Crafoord, J., Koh, Y., White, D., Mellqvist, U., Leip, E. P., Kudla, A. J., Finn, G., & Pruchniewski, Ł. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.tps8074 · Cited by 15
Dhakal, B., Einsele, H., Potluri, R., Schecter, J., Deraedt, W., Lendvai, N., Slaughter, A., Lonardi, C., Nair, S., He, J., et al. (2022) · HemaSphere · doi:10.1097/01.hs9.0000846468.64341.f1 · Cited by 9
Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies
Cani, L., Scott, S. A., Joseph, N. S., Hofmeister, C. C., Gupta, V. A., Dhodapkar, M. V., Lonial, S., Nooka, A. K., & Kaufman, J. L. (2024) · Blood · doi:10.1182/blood-2024-206155 · Cited by 9 · cited 1×
“36– 40 Notably, Tec-Dara was administered per approved daratumumab dosing schedule, with monthly teclistamab dosing from cycle 7 onwards, potentially easing treatment burden and providing a regimen familiar to healthcare providers.”
Self-citationWeisel, K. C., Hungria, V., Quach, H., Yoon, S., Rodríguez‐Otero, P., Kroog, G. S., Sinha, A., Boyapati, A., Lyon, C., Lorenc, K. R., et al. (2023) · HemaSphere · doi:10.1097/01.hs9.0000975296.46536.6a · Cited by 6 · cited 1×
“26,28 Other bispecific antibodies with activity in advanced myeloma and targeting BCMA, elranatamab 29 and linvoseltamab, 30 as well as GPRC5D, talquetamab, 31 are being evaluated in earlier line RRMM. Tec-Dara is a synergistic immunotherapy combination that utilizes subcutaneous administration,…”
Self-citationGarfall, A. L., Nooka, A. K., van de Donk, N. W. C. J., et al. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(24)00953-4 · Cited by 4
Self-citationBeer, T. C., Graf, G. H., Lin, D., Fernandez, M., Doyle, M., Hester, L. L., Wu, B., & Huo, S. (2024) · Blood · doi:10.1182/blood-2024-203379 · Cited by 3
Nierengarten, M. B. (2025) · Cancer · doi:10.1002/cncr.70014 · Cited by 3
Cited by
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy
Touzeau, C., Mina, R., Quach, H., Hungria, V., Bhutani, D., Chen, W., Kumar, S. S., Chaulagain, C. P., Dimopoulos, M. A., Bahlis, N. J., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2603870 · Cited by 39
Self-citationTalquetamab–Daratumumab in Relapsed or Refractory Myeloma
Mina, R., Beksac, M., Rodríguez‐Otero, P., Chen, W., Mateos, M., Li, J., Moreau, P., Cohen, Y. C., Min, C., Jelínek, T., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2604657 · Cited by 28
Self-citationvan de Donk, N. W. C. J., Sonneveld, P., & Einsele, H. (2026) · Blood · doi:10.1182/blood.2025032536 · Cited by 15
Raab, M. S., Weinhold, N., Kortüm, K. M., Krönke, J., Fenk, R. R., Weisel, K. C., Podola, L., Bertsch, U., Brobeil, A., Mersi, J., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04471-x · Cited by 11
Self-citationGagelmann, N., Einsele, H., Flossdorf, S., Smaili, S., Metzeler, K., Scheid, C., Bullinger, L., Sauer, S., Raab, M., Duyster, J., et al. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01806-6 · Cited by 5
“…results of the MajesTEC-3 trial, which demonstrated an 83% reduction in the risk of progression or death with teclistamab plus daratumumab in a similar second-line population [34], introduce bispecific antibody-based combinations as a potentially competing strategy in the same therapeutic space.”
Self-citation
Metadata
- Authors
- Costa, L. J., Bahlis, N. J., Perrot, A., Nooka, A. K., Lu, J., Pawlyn, C., Mina, R., Caeiro, G., Kentos, A., Hungria, V., Reece, D., Niu, T., Mylin, A. K., Hansen, C. T., Teipel, R., Besemer, B., Dimopoulos, M. A., Zamagni, E., Yoshihara, S., Kim, K., Min, C. K., Geerts, P., Van Leeuwen-Segarceanu, E., Tyczynska, A., Reguera, J. L., Johansson, M., Hansson, M., Turgut, M., Grey, M., Sidana, S., Rodriguez-Otero, P., Martinez-Lopez, J., Hashmi, H., Carson, R., Kobos, R., Sun, W., Lantz, K., Seifert, A., Briseno-Toomey, D., O’Rourke, L., Rubin, M., Vieyra, D., Kang, L., & Mateos, M. V.
- Affiliations
- University of Alabama at Birmingham (US)
- University of Calgary (CA)
- Centre Hospitalier Universitaire de Toulouse (FR)
- Winship Cancer Institute (US)
- Peking University People's Hospital (CN)
- Royal Marsden NHS Foundation Trust (GB)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Hospital Privado Universitario de Córdoba Instituto Universitario de Ciencias Biomédicas de Córdoba, Córdoba, Argentina
- Hôpital de Jolimont (BE)
- Clinica São Germano, São Paulo
- Princess Margaret Cancer Centre (CA)
- Sichuan University (CN)
- Rigshospitalet (DK)
- Odense University Hospital (DK)
- University Hospital Carl Gustav Carus (DE)
- University of Tübingen (DE)
- Korea University (KR)
- Istituto di Ematologia di Bologna (IT)
- Hyogo Medical University Hospital (JP)
- Division of Hematology–Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Isala (NL)
- St. Antonius Ziekenhuis (NL)
- Department of Hematology and Transplantology, Medical University of Gdansk; Department of Hematology and Transplantology, University Clinical Center, Gdansk, Poland
- Instituto de Biomedicina de Sevilla (ES)
- Sunderby sjukhus (SE)
- Sahlgrenska University Hospital (SE)
- Ondokuz Mayıs University (TR)
- Blackpool Victoria Hospital (GB)
- Stanford Medicine (US)
- Cancer Center Clínica Universidad de Navarra, Pamplona, Spain
- Hematology Department, Instituto de Investigación Hospital 12 de Octubre, Universidad Complutense, Centro Nacional de Investigaciones Oncológicas, Centro de Investigación Biomédica en Red de Cáncer, Madrid
- Memorial Sloan Kettering Cancer Center (US)
- Johnson & Johnson (United States) (US)
- Johnson & Johnson (United Kingdom) (GB)
- Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer (Universidad de Salamanca–Consejo Superior de Investigaciones Científicas), Centro de Investigación Biomédica en Red de Cáncer, Salamanca, Spain
- ORCID
- Costa, Luciano J.
- Bahlis, Nizar J.
- Perrot, Aurore
- Nooka, Ajay K.
- Lu, Jin
- Pawlyn, Charlotte
- Mina, Roberto
- Kentos, Alain
- Reece, Donna
- Niu, Ting
- Teipel, Raphael
- Dimopoulos, Meletios A.
- Zamagni, Elena
- Yoshihara, Satoshi
- Min, Chang Ki
- Geerts, Paul
- Reguera, Juan Luis
- Hansson, Markus
- Turgut, Mehmet
- Sidana, Surbhi
- Hashmi, Hamza
- Kang, Lijuan
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2026-02-19
- Volume
- 394
- Issue
- 8
- Pages
- 739-752
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC13218738
- OpenAlex
- W4417156840
- Cited by
- 119
- References
- 35
- Citations by year
- 2026: 117
- FWCI
- 81.61
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- University of Southern Denmark Research Portal (University of Southern Denmark) (acceptedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Johnson & Johnson
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- teclistamab, daratumumab, relapsed/refractory multiple myeloma, bispecific antibodies, CD38, progression-free survival, dexamethasone, pomalidomide, bortezomib, combination therapy, adverse events
- MeSH terms
- Bortezomib, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Thalidomide, Time Factors, Antibodies, Bispecific, Drug Resistance, Neoplasm, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.